Generic Sterile Injectables Market
完整報告名稱與涵蓋範圍
Generic Sterile Injectables Market Size, Share & Trends Analysis Report, By Product Type (Small-Molecule Generic Injectables, Complex Generic Injectables (Liposomal, Depot, Emulsions), Generic Peptide Injectables, 505(b)(2) and Ready-to-Use Injectable Formats), By Container Format (Vials and Ampoules, Prefilled Syringes, Premixed Bags and Cartridges), By Therapeutic Area (Oncology, Anesthesia, Analgesia and Critical Care, Anti-Infectives, Cardiovascular, Endocrine and Other Areas), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The generic sterile injectables market covers off-patent injectable medicines manufactured by generic and specialty companies, including conventional small-molecule injectables, complex formulations such as liposomes and depots, generic peptide injectables and 505(b)(2) or ready-to-use presentations supplied primarily to hospitals, infusion centers and specialty pharmacies. Branded injectables, biosimilars and vaccines are excluded. Regional editions, including Europe, are addressed within the global analysis rather than as separate records.
Demand is underpinned by hospital reliance on injectables for anesthesia, oncology, critical care and anti-infective therapy, by a steady stream of patent expiries on complex injectables and by the growth of ready-to-use formats that reduce preparation errors. The sector has been marked by persistent shortages caused by thin margins, manufacturing quality failures and concentrated supply, prompting governments and purchasers to reward supply reliability, domestic capacity and quality track records. Manufacturers are investing in isolator-based lines, premixed bags and prefilled syringes, and complex generics with higher barriers to entry offer margin relief compared with commoditised vials.
North America is the largest market by value, Europe follows with tender-driven pricing across national systems, and India-based manufacturers supply a growing share of global volume alongside expanding Chinese producers. Competition spans global generic groups, sterile specialists and Indian and Chinese manufacturers with regulatory approvals in developed markets.
The InsightAce study supplies US$ forecasts for all product type, container format, therapeutic area and end user and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Generic Sterile Injectables Market Snapshot
Chapter 4. Global Generic Sterile Injectables Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Product Type Estimates & Trend Analysis
5.1. Product Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Product Type:
5.2.1. Small-Molecule Generic Injectables
5.2.2. Complex Generic Injectables (Liposomal, Depot, Emulsions)
5.2.3. Generic Peptide Injectables
5.2.4. 505(b)(2) and Ready-to-Use Injectable Formats
Chapter 6. Market Segmentation 2: By Container Format Estimates & Trend Analysis
6.1. Container Format & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Container Format:
6.2.1. Vials and Ampoules
6.2.2. Prefilled Syringes
6.2.3. Premixed Bags and Cartridges
Chapter 7. Market Segmentation 3: By Therapeutic Area Estimates & Trend Analysis
7.1. Therapeutic Area & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Therapeutic Area:
7.2.1. Oncology
7.2.2. Anesthesia, Analgesia and Critical Care
7.2.3. Anti-Infectives
7.2.4. Cardiovascular, Endocrine and Other Areas
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Hospitals and Group Purchasing Organizations
8.2.2. Ambulatory Surgical and Infusion Centers
8.2.3. Retail and Specialty Pharmacies
Chapter 9. Generic Sterile Injectables Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Fresenius Kabi AG
11.2. Pfizer Inc. (Hospira)
11.3. Hikma Pharmaceuticals PLC
11.4. Teva Pharmaceutical Industries Ltd.
11.5. Sandoz Group AG
11.6. Viatris Inc.
11.7. Baxter International Inc.
11.8. Dr. Reddy's Laboratories Ltd.
11.9. Sun Pharmaceutical Industries Ltd.
11.10. Amneal Pharmaceuticals, Inc.
11.11. Gland Pharma Limited
11.12. Aurobindo Pharma Ltd. (Eugia)
11.13. Cipla Ltd.
11.14. Xellia Pharmaceuticals
11.15. Zydus Lifesciences Ltd.
圖表清單 List of Tables & Figures
Table 1. Global Generic Sterile Injectables Revenue Forecast by Product Type, 2026-2035 (US$ Mn)
Figure 1. Global Generic Sterile Injectables Market Snapshot, 2026 & 2035
Table 2. Global Generic Sterile Injectables Revenue Forecast by Container Format, 2026-2035 (US$ Mn)
Figure 2. Global Generic Sterile Injectables Market Share by Container Format, 2026 & 2035
Table 3. Global Generic Sterile Injectables Revenue Forecast by Therapeutic Area, 2026-2035 (US$ Mn)
Figure 3. Injectable Drug Shortage Drivers and Policy Responses by Region
Table 4. Global Generic Sterile Injectables Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Complex Generic Injectable Pipeline and Patent Expiry Calendar, 2026-2032
Table 5. North America Generic Sterile Injectables Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Generic Sterile Injectables Growth Opportunity Analysis
Table 6. Europe Generic Sterile Injectables Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Ready-to-Use and Prefilled Format Adoption in Hospital Injectables
Table 7. Asia Pacific Generic Sterile Injectables Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key Generic Sterile Injectables Market Participants
Table 8. Latin America and Middle East & Africa Generic Sterile Injectables Revenue Forecast, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們